The sensitivity of Hodgkin's disease to chemotherapeutic agents administered singly.
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use*; D000505:Alopecia / Q000139:chemically induced; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001761:Bleomycin / Q000627:therapeutic use; D001791:Blood Platelet Disorders / Q000139:chemically induced; D002330:Carmustine / Q000627:therapeutic use; D002699:Chlorambucil / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D003630:Daunorubicin / Q000627:therapeutic use; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008466:Mechlorethamine / Q000627:therapeutic use; D008936:Mitolactol / Q000627:therapeutic use; D009422:Nervous System Diseases / Q000139:chemically induced; D011344:Procarbazine / Q000627:therapeutic use; D012075:Remission, Spontaneous; D013308:Streptonigrin / Q000627:therapeutic use; D014747:Vinblastine / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use
D000305:Adrenal Cortex Hormones; D000970:Antineoplastic Agents; D001761:Bleomycin; D002699:Chlorambucil; D013308:Streptonigrin; D011344:Procarbazine; D008466:Mechlorethamine; D014750:Vincristine; D014747:Vinblastine; D003520:Cyclophosphamide; D008936:Mitolactol; D002330:Carmustine; D003630:Daunorubicin